FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2178788082> ?p ?o ?g. }

• W2178788082 endingPage "463" @default.
• W2178788082 startingPage "463" @default.
• W2178788082 abstract "I received the ‘Business of medicine’ within weeks of finishing John Le Carre's latest novel ‘The Constant Gardener’. Both are about the pharmaceutical industry. Le Carre's book is a fictional expose, in an African setting, of intrigue and skullduggery by an unnamed multinational. Edgar Jones provides a factual account of the gestation, infancy, adolescence and maturity of one such industrial giant. There could hardly be a greater contrast!Edgar Jones and his assistant, John Savage, have produced a prodigiously researched volume which reads easily despite occasional turgid passages when we are taken through profit and loss accounts, intercompany negotiations, and rearrangements of plant and personnel.While other companies have also had humble beginnings, the origins of Glaxo in Nathans' general store in Wellington, New Zealand, in 1861, gave no hint of developments to come. The Nathans made dried milk, often modified to improve suitability for babies by the addition of milk sugar (whence the name ‘Glaxo’ – ‘an ephonious (sic) word’ derived from ‘lactose’). As the company, now located in London, grew, pharmaceuticals crept in by the side door – vitamins to fortify infant foods, and then stand-alone vitamin D, an important additive in the early decades of last century when rickets abounded. In the Second World War Glaxo, together with other companies, became involved in the production of penicillin. Post-war the company made and marketed antibiotics, and in the 1950s moved into steroid research. From the 1960s onwards the emphasis moved more exclusively to new drug discovery, and the increasing success of the company in the later decades of the 20th century was founded on the establishment of excellent research teams, sound direction and also more than a measure of luck. The discovery of salbutamol in 1966 exploited the newly recognized diversity of β-adrenergic receptors. Building on this came labetalol – a combined α- and β-receptor antagonist in 1977. But the block-buster, ranitidine, on which the later fortunes of Glaxo were built, was not the first of its kind, the selective inhibition of gastric histamine H2-receptors having been pioneered by James Black and colleagues working with Smith Kline and French (SKF). It was SKF who launched the first commercially successful H2-receptor blocker, cimetidine, and Glaxo's ranitidine had to compete against a well-established therapy. The marketing strategy was to emphasize the (in most cases) relatively minor clinical advantages of ranitidine and exact a financial premium as a consequence. The strategy worked, and the fortunes of Glaxo were secured.For me the most interesting sections of this book were the early company history with its photographs, the very well written account of research and development in recent years, and the history of the establishment and growth of Glaxo in the USA.My disappointments were the lack of any real definition of the personalities of those who led (and lead) the company, the almost total lack of reference to industrial relations, and the overall feeling that this book was written from a desk placed securely in the Board Room. There are more than 1800 notes and references, and the preponderant sources are Board minutes and interviews with Board members and company executives.Orphan drugs get a tiny mention, but nowhere are the economic realities of the present day touched upon, or the attitude of the company to research into treatments for, for example, prevalent diseases of poorer countries.I enjoyed reading the ‘Business of Medicine’, and it will find a place on my library shelves – probably alongside ‘The Constant Gardener’." @default.
• W2178788082 created "2016-06-24" @default.
• W2178788082 creator A5029924296 @default.
• W2178788082 date "2001-10-01" @default.
• W2178788082 modified "2023-09-26" @default.
• W2178788082 title "The business of medicine, a history of Glaxo" @default.
• W2178788082 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2014575" @default.
• W2178788082 hasPublicationYear "2001" @default.
• W2178788082 type Work @default.
• W2178788082 sameAs 2178788082 @default.
• W2178788082 citedByCount "0" @default.
• W2178788082 crossrefType "journal-article" @default.
• W2178788082 hasAuthorship W2178788082A5029924296 @default.
• W2178788082 hasConcept C137355542 @default.
• W2178788082 hasConcept C158016649 @default.
• W2178788082 hasConcept C162324750 @default.
• W2178788082 hasConcept C17744445 @default.
• W2178788082 hasConcept C187736073 @default.
• W2178788082 hasConcept C199539241 @default.
• W2178788082 hasConcept C6303427 @default.
• W2178788082 hasConcept C71924100 @default.
• W2178788082 hasConcept C74916050 @default.
• W2178788082 hasConcept C95457728 @default.
• W2178788082 hasConceptScore W2178788082C137355542 @default.
• W2178788082 hasConceptScore W2178788082C158016649 @default.
• W2178788082 hasConceptScore W2178788082C162324750 @default.
• W2178788082 hasConceptScore W2178788082C17744445 @default.
• W2178788082 hasConceptScore W2178788082C187736073 @default.
• W2178788082 hasConceptScore W2178788082C199539241 @default.
• W2178788082 hasConceptScore W2178788082C6303427 @default.
• W2178788082 hasConceptScore W2178788082C71924100 @default.
• W2178788082 hasConceptScore W2178788082C74916050 @default.
• W2178788082 hasConceptScore W2178788082C95457728 @default.
• W2178788082 hasIssue "4" @default.
• W2178788082 hasLocation W21787880821 @default.
• W2178788082 hasOpenAccess W2178788082 @default.
• W2178788082 hasPrimaryLocation W21787880821 @default.
• W2178788082 hasRelatedWork W118206276 @default.
• W2178788082 hasRelatedWork W1506492886 @default.
• W2178788082 hasRelatedWork W1614272729 @default.
• W2178788082 hasRelatedWork W1687644735 @default.
• W2178788082 hasRelatedWork W1737608830 @default.
• W2178788082 hasRelatedWork W195787109 @default.
• W2178788082 hasRelatedWork W2006407474 @default.
• W2178788082 hasRelatedWork W2024225600 @default.
• W2178788082 hasRelatedWork W2061989194 @default.
• W2178788082 hasRelatedWork W2062080364 @default.
• W2178788082 hasRelatedWork W2065226772 @default.
• W2178788082 hasRelatedWork W2087319624 @default.
• W2178788082 hasRelatedWork W2119824304 @default.
• W2178788082 hasRelatedWork W2125492425 @default.
• W2178788082 hasRelatedWork W2159294568 @default.
• W2178788082 hasRelatedWork W2192427787 @default.
• W2178788082 hasRelatedWork W2401638891 @default.
• W2178788082 hasRelatedWork W77820122 @default.
• W2178788082 hasRelatedWork W1685240787 @default.
• W2178788082 hasRelatedWork W2078508995 @default.
• W2178788082 hasVolume "52" @default.
• W2178788082 isParatext "false" @default.
• W2178788082 isRetracted "false" @default.
• W2178788082 magId "2178788082" @default.
• W2178788082 workType "article" @default.